Hainan Shuangcheng Pharmaceut (002693) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has a cash flow conversion efficiency ratio of 0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.67 Million ≈ $4.93 Million USD) by net assets (CN¥404.35 Million ≈ $59.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Hainan Shuangcheng Pharmaceut to measure how much of total assets are equity-financed.
Hainan Shuangcheng Pharmaceut - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Hainan Shuangcheng Pharmaceut's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hainan Shuangcheng Pharmaceut (002693) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Hainan Shuangcheng Pharmaceut Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang MustangBattery Co.Ltd
SHG:605378
|
-0.029x |
|
Zhejiang Netsun Co Ltd
SHE:002095
|
0.015x |
|
AUPU Home Style Corp Ltd
SHG:603551
|
0.023x |
|
Sichuan Expressway Company Limited
F:EXF1
|
0.060x |
|
Yoantion Industrial Inc.Ltd.
SHE:301053
|
N/A |
|
Shenzhen King Explorer Science and Technology Corp Class A
SHE:002917
|
0.035x |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
0.058x |
|
Song Da Urban & Industrial Zone Investment and Development JSC
VN:SJS
|
-0.118x |
Annual Cash Flow Conversion Efficiency for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below shows the annual cash flow conversion efficiency of Hainan Shuangcheng Pharmaceut from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 002693 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥420.53 Million ≈ $61.54 Million |
CN¥60.95 Million ≈ $8.92 Million |
0.145x | +246.12% |
| 2024-12-31 | CN¥411.61 Million ≈ $60.23 Million |
CN¥-40.83 Million ≈ $-5.97 Million |
-0.099x | -541.12% |
| 2023-12-31 | CN¥517.65 Million ≈ $75.75 Million |
CN¥11.64 Million ≈ $1.70 Million |
0.022x | -48.20% |
| 2022-12-31 | CN¥580.94 Million ≈ $85.01 Million |
CN¥25.22 Million ≈ $3.69 Million |
0.043x | +4.45% |
| 2021-12-31 | CN¥566.75 Million ≈ $82.93 Million |
CN¥23.55 Million ≈ $3.45 Million |
0.042x | +336.77% |
| 2020-12-31 | CN¥598.31 Million ≈ $87.55 Million |
CN¥-10.50 Million ≈ $-1.54 Million |
-0.018x | -117.88% |
| 2019-12-31 | CN¥678.26 Million ≈ $99.25 Million |
CN¥66.58 Million ≈ $9.74 Million |
0.098x | +40.36% |
| 2018-12-31 | CN¥669.69 Million ≈ $98.00 Million |
CN¥46.84 Million ≈ $6.85 Million |
0.070x | +336.39% |
| 2017-12-31 | CN¥761.71 Million ≈ $111.46 Million |
CN¥-22.54 Million ≈ $-3.30 Million |
-0.030x | -142.35% |
| 2016-12-31 | CN¥553.13 Million ≈ $80.94 Million |
CN¥38.65 Million ≈ $5.66 Million |
0.070x | +40.17% |
| 2015-12-31 | CN¥927.61 Million ≈ $135.74 Million |
CN¥46.24 Million ≈ $6.77 Million |
0.050x | -12.67% |
| 2014-12-31 | CN¥893.55 Million ≈ $130.75 Million |
CN¥51.00 Million ≈ $7.46 Million |
0.057x | -11.95% |
| 2013-12-31 | CN¥870.62 Million ≈ $127.40 Million |
CN¥56.43 Million ≈ $8.26 Million |
0.065x | -31.65% |
| 2012-12-31 | CN¥845.85 Million ≈ $123.77 Million |
CN¥80.22 Million ≈ $11.74 Million |
0.095x | -67.23% |
| 2011-12-31 | CN¥228.23 Million ≈ $33.40 Million |
CN¥66.05 Million ≈ $9.67 Million |
0.289x | -17.45% |
| 2010-12-31 | CN¥157.82 Million ≈ $23.09 Million |
CN¥55.33 Million ≈ $8.10 Million |
0.351x | -38.27% |
| 2009-12-31 | CN¥77.95 Million ≈ $11.41 Million |
CN¥44.27 Million ≈ $6.48 Million |
0.568x | -- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more